ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Takeda considers a takeover of Shire

by Ryan Cross
April 2, 2018 | APPEARED IN VOLUME 96, ISSUE 14

Takeda Pharmaceutical says it is considering making a takeover offer for Shire, well-known for its rare disease and attention-deficit/hyperactivity disorder drugs. Takeda says the move would reinforce its oncology, gastrointestinal, and neuroscience drug programs. Shire’s shares soared 18% on the news. Shire, whose market capitalization is more than $45 billion—slightly higher than Takeda’s—says it has yet to receive an offer from the Japanese firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment